Drug Trial Radar · NCT01058707
Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies
Last checked: Nov 20, 2026Latest source record: Apr 1, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
198
Actual
Start
Jan 4, 2010
Primary completion
Feb 7, 2019
Study completion Feb 7, 2019
Sponsor
- Lead sponsor
- Millennium Pharmaceuticals, Inc.Takeda (TAK)
- Sponsor type
- Industry
- First posted
- Jan 29, 2010
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase I, open label, Dose Escalation study of oral administration of single agent MLN0128 in participants with Advanced Malignancies followed by an Expansion Phase in participants with renal cell carcinoma, endometrial cancer or urothelial cancer who have measurable disease.
Conditions
- Advanced Solid Malignancies
Interventions
MLN0128Drug
MLN0128 capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Escalation Phase: Maximum Tolerated Dose (MTD)Time frame: Cycle 1 (28 Days)
- Dose Escalation Phase: Number of Participants With Dose Limiting Toxicities (DLTs)Time frame: Cycle 1 (28 days)
- Number of Participants Experiencing One or More Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), AEs Resulting in Discontinuation of MLN0128 and Fatal AEs Within 30 Days of Last Dose of Study DrugTime frame: First dose of study drug through 30 days after the administration of the last dose of study drug (Up to approximately 244 weeks)
- Dose Expansion: Objective Response Rate (ORR)Time frame: From the first dose of study drug up to disease progression or death (Up to approximately 240 weeks)
- Dose Expansion Phase: Duration of Objective ResponseTime frame: From the first dose of study drug up to disease progression or death (Up to approximately 240 weeks)
- Dose Expansion: Duration of Stable Disease (SD)Time frame: From the first dose of study drug up to disease progression or death (Up to approximately 240 weeks)
Locations
16 sites in 2 countries. Site status is shown where the registry gives one.
Site not named
Scottsdale, Arizona
Site not named
Los Angeles, California
Site not named
Miami, Florida
Site not named
Sarasota, Florida
Site not named
Indianapolis, Indiana
Site not named
Boston, Massachusetts
Site not named
Ann Arbor, Michigan
Site not named
Detroit, Michigan
Site not named
Buffalo, New York
Site not named
New York, New York
Site not named
Cleveland, Ohio
Site not named
Oklahoma City, Oklahoma
Site not named
Philadelphia, Pennsylvania
Site not named
Nashville, Tennessee
Site not named
Barcelona, Spain
Site not named
Valencia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.